Start-Up Spotlight: Pertinax Pharma, Closing In On Wound Care With Slow-Release CHX Tech
A UK drug-delivery firm is bringing its antimicrobial material to the global wound-care market. Pertinax Pharma, a Bristol University spin-out, is the developer of a slow-release technology that provides controlled and sustained delivery of the antiseptic chlorhexidine.
You may also be interested in...
Acelity has agreed to acquire Crawford Healthcare for an undisclosed price to expand its wound care portfolio. Crawford's wound-dressing portfolio includes the KerraMax Care, KerraFoam, and KerraCel brands, complementing Acelity's advanced wound dressing line-up, which includes the Promogran Prisma Matrix collagen dressing, the Tielle dressings, and Adaptic dressings. The deal also includes Crawford's research and development and manufacturing facilities in Chesire, UK.
Emerging drug delivery firm Pertinax has hired a new business development manager to lead commercialization of its technology in the wound care market.
Briston University spin-out and developer of an antimicrobial material Pertinax Pharma has appointed Nigel Brooksby as chairman.